Über uns
Dr Farasat Kazmi is a Consultant Clinical Oncologist specialising in lung cancer, with particular expertise in advanced radiotherapy techniques including Stereotactic Ablative Radiotherapy (SABR). He treats lung cancer across all stages, from early-stage disease to locally advanced and metastatic cancer, using modern radiotherapy alongside chemotherapy, immunotherapy, and precision-targeted therapies guided by molecular profiling.
Dr Kazmi has a strong academic and research background and holds an MSc in Nanomedicine from the University of Oxford. He previously worked in the Early Phase Clinical Trials Unit at the Churchill Hospital, Oxford, where he was involved in first-in-human and novel targeted therapy studies. He is the Principal Investigator on three international lung cancer clinical trials and has played a leading role in Cochrane systematic reviews on genomic-guided cancer therapies, ensuring his clinical practice is firmly grounded in the highest-quality evidence.
He is actively involved in precision oncology, leading institutional initiatives focused on integrating molecular testing and personalised treatment strategies into routine cancer care. His work has been recognised through national and international awards, including competitive oncology research and education grants.
In addition to lung cancer, Dr Kazmi treats gynaecological cancers, including ovarian cancer, and non-melanoma skin cancers.
He is known for his clear communication, calm manner, and patient-centred approach, taking time to explain diagnoses and treatment options and supporting shared decision-making throughout the cancer journey.
Dr Kazmi has a strong academic and research background and holds an MSc in Nanomedicine from the University of Oxford. He previously worked in the Early Phase Clinical Trials Unit at the Churchill Hospital, Oxford, where he was involved in first-in-human and novel targeted therapy studies. He is the Principal Investigator on three international lung cancer clinical trials and has played a leading role in Cochrane systematic reviews on genomic-guided cancer therapies, ensuring his clinical practice is firmly grounded in the highest-quality evidence.
He is actively involved in precision oncology, leading institutional initiatives focused on integrating molecular testing and personalised treatment strategies into routine cancer care. His work has been recognised through national and international awards, including competitive oncology research and education grants.
In addition to lung cancer, Dr Kazmi treats gynaecological cancers, including ovarian cancer, and non-melanoma skin cancers.
He is known for his clear communication, calm manner, and patient-centred approach, taking time to explain diagnoses and treatment options and supporting shared decision-making throughout the cancer journey.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Dr Farasat Kazmi
Ausbildung & Training
-
2017–2023 MD · Medicine and Surgery
-
2023–2027 Residency · Onkologie
Karriere & Anstellungen
-
2027-09–2028-08 Junior consultant
Lizenzen & Versicherung
Medizinische Lizenzen
GB — Organización Médica Colegial de España (OMC)
Facharztzertifikate
European Board of Onkologie
Berufshaftpflichtversicherung:
Generali Healthcare · 1,000,000 EUR Deckung · No claims on file
Durchgeführte Verfahren
| Verfahren | Code | Lebenszeit-Anzahl |
|---|---|---|
| GP consultation | 99213 | 2,383 |
| Annual physical exam | 99395 | 825 |
| Vaccination administration | 90471 | 217 |
| Minor procedure (skin) | 17110 | 230 |
Leistungen & Preise
| Leistung | Dauer | Modalität | Preis |
|---|---|---|---|
| New patient consultation (60m) | 60 Min. | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 Min. | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 30 Min. | in_clinic | 630.00 EUR |
| Minor procedure (skin) | 120 Min. | in_clinic | 720.00 EUR |
Praxis, Team & in der Praxis
Videos
Forschung & Publikationen
h-Index: 5 · i10: 4
-
Long-term follow-up of Onkologie across GB
DOI: 10.5950/euroclin.2026.0 · PMID: 31322945 · zitiert von 39
-
Validation of clinical scoring in Onkologie
DOI: 10.4876/euroclin.2025.1 · PMID: 36082719 · zitiert von 165
Eingeladene Vorträge
- Practical updates in Onkologie European Annual Congress (Onkologie) · Vienna · 2024 · invited
- Single-centre experience in Onkologie National Society Meeting · Newmarket · 2023 · oral abstract
Auszeichnungen & Mitgliedschaften
Auszeichnungen
- 🏆 Top-rated Onkologie — Newmarket · EuroClinics Patient Choice · 2025 · regional
Gesellschaftsmitgliedschaften
- WONCA Europe — Family Doctors — Member · Seit 2028
- national college of family doctors — Member · Seit 2028
- European Union of Medical Specialists (UEMS) — Member · Seit 2028
Artikel dieses Arztes
- Patient education Patient guide to Onkologie
- Awareness When should you see a onkologie?
Für internationale Patienten
- Koordinator
- Patient liaison · farasat.kazmi@euroclinics.example
Standort
1 TagPatientenbewertungen
Teilen Sie Ihre Erfahrung — Helfen Sie anderen Patienten, den richtigen Arzt zu finden. Bewertung schreiben →
Aktuelle Bewertungen
-
★★★★★ ✓ Verifiziert Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.
-
★★★★★ ✓ Verifiziert Took time to listen and reviewed all my previous results. I would absolutely recommend.
-
★★★★☆ ✓ Verifiziert Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.
Ähnliche Spezialisten
Alle durchsuchen →
Dr Mark Nathan
Onkologie · London
Dr Daniel Hochhauser
Onkologie · London
Mr Henry Taylor
Onkologie · Maidstone
Dr Charlotte Rees
Onkologie · Winchester
Professor Hany Mohamad Eldeeb
Onkologie · Milton Keynes
Dr Melanie Powell
Onkologie · London
Professor Jonathan Ledermann
Onkologie · London
Professor Siow Ming Lee
Onkologie · London